Current treatments for neurodegenerative diseases like Alzheimer's and Parkinson's often lack precision, failing to address the specific neural pathways affected in individual patients. This can lead to limited efficacy and unwanted side effects.

NeuralGalaxy develops targeted neurobiological therapies for brain disorders, focusing on Alzheimer's and Parkinson's disease. The company leverages advanced neuroimaging techniques and biomarker analysis to identify and target specific neural pathways implicated in these conditions. By understanding the unique neurobiological profile of each patient, NeuralGalaxy aims to deliver personalized treatments that maximize therapeutic benefits while minimizing adverse effects. This precision medicine approach seeks to improve patient outcomes by addressing the root causes of neurodegeneration at the individual level.

Advanced neuroimaging analysis to map neural pathway activity and identify disease-specific biomarkers.

Proprietary algorithms for personalized treatment planning based on individual neurobiological profiles.

Targeted drug delivery systems designed to reach specific brain regions and neural circuits.

Clinical trials evaluating the efficacy and safety of personalized neurobiological therapies.

NeuralGalaxy's primary customers are patients diagnosed with Alzheimer's and Parkinson's disease, as well as neurologists and other healthcare providers specializing in neurodegenerative disorders.